

Digby F Warner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4380965/publications.pdf>

Version: 2024-02-01

134
papers

3,394
citations

147566

31
h-index

189595

50
g-index

153
all docs

153
docs citations

153
times ranked

4366
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of 4-aminopyrrolo[2,3-d]pyrimidine as antitubercular agents. <i>Molecular Diversity</i> , 2023, 27, 753-765.	2.1	2
2	Molecular Detection of Airborne <i>Mycobacterium tuberculosis</i> in South African High Schools. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 350-356.	2.5	10
3	Estimating Tuberculosis Transmission Risks in a Primary Care Clinic in South Africa: Modeling of Environmental and Clinical Data. <i>Journal of Infectious Diseases</i> , 2022, 225, 1642-1652.	1.9	5
4	Identification of Antimycobacterial Natural Products from a Library of Marine Invertebrate Extracts. <i>Medicines (Basel, Switzerland)</i> , 2022, 9, 9.	0.7	2
5	DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits Replication in <i>Mycobacterium tuberculosis</i> . <i>ACS Infectious Diseases</i> , 2022, 8, 612-625.	1.8	11
6	Serial measurement of <i>M. tuberculosis</i> in blood from critically-ill patients with HIV-associated tuberculosis. <i>EBioMedicine</i> , 2022, 78, 103949.	2.7	5
7	New Quinoline-Urea-Benzothiazole Hybrids as Promising Antitubercular Agents: Synthesis, In Vitro Antitubercular Activity, Cytotoxicity Studies, and In Silico ADME Profiling. <i>Pharmaceuticals</i> , 2022, 15, 576.	1.7	11
8	Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis. <i>Scientific Reports</i> , 2022, 12, 7919.	1.6	3
9	Antiplasmodial and antimycobacterial activities of crude and lead-like enhanced extracts from Namibian medicinal plants. <i>Journal of Ethnopharmacology</i> , 2022, , 115389.	2.0	0
10	Aerosolization of <i>Mycobacterium tuberculosis</i> by Tidal Breathing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 206-216.	2.5	30
11	Cough-independent production of viable <i>Mycobacterium tuberculosis</i> in bioaerosol. <i>Tuberculosis</i> , 2021, 126, 102038.	0.8	18
12	Antimycobacterial, Cytotoxic, and Antioxidant Activities of Abietane Diterpenoids Isolated from <i>Plectranthus madagascariensis</i> . <i>Plants</i> , 2021, 10, 175.	1.6	8
13	Easy-To-Access Quinolone Derivatives Exhibiting Antibacterial and Anti-Parasitic Activities. <i>Molecules</i> , 2021, 26, 1141.	1.7	7
14	Propylphosphonic acid anhydride-mediated amidation of Morita-Baylis-Hillman-derived indolizine-2-carboxylic acids. <i>Journal of Chemical Research</i> , 2021, 45, 674-678.	0.6	0
15	<i>De Novo</i> Cobalamin Biosynthesis, Transport, and Assimilation and Cobalamin-Mediated Regulation of Methionine Biosynthesis in <i>Mycobacterium smegmatis</i> . <i>Journal of Bacteriology</i> , 2021, 203, .	1.0	5
16	Easily accessed nitroquinolones exhibiting potent and selective anti-tubercular activity. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113207.	2.6	8
17	Synthesis and antimicrobial study of organoiridium amido-sulfadoxine complexes. <i>Inorganica Chimica Acta</i> , 2021, 517, 120175.	1.2	8
18	Developing Synergistic Drug Combinations To Restore Antibiotic Sensitivity in Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	16

#	ARTICLE	IF	CITATIONS
19	Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against <i>Mycobacterium tuberculosis</i> . <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2021, 2021, 1-8.	0.7	0
20	Benzoheterocyclic Oxime Carbamates Active against <i>Mycobacterium tuberculosis</i> : Synthesis, Structure-Activity Relationship, Metabolism, and Biology Triaging. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9444-9457.	2.9	10
21	Imaging Africa: a strategic approach to optical microscopy training in Africa. <i>Nature Methods</i> , 2021, 18, 847-855.	9.0	4
22	Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone. <i>Bioorganic Chemistry</i> , 2021, 114, 105118.	2.0	11
23	Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy. <i>Microbiology Spectrum</i> , 2021, 9, e0043421.	1.2	6
24	Isolation and characterization of new phenolic siderophores with antimicrobial properties from <i>Pseudomonas</i> sp. UIAU-6B. <i>Beilstein Journal of Organic Chemistry</i> , 2021, 17, 2390-2398.	1.3	3
25	Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria. <i>Scientific Reports</i> , 2021, 11, 18661.	1.6	11
26	Capture and visualization of live <i>Mycobacterium tuberculosis</i> bacilli from tuberculosis patient bioaerosols. <i>PLoS Pathogens</i> , 2021, 17, e1009262.	2.1	30
27	Cell Wall Proteomics Reveal Phenotypic Adaption of Drug-Resistant <i>Mycobacterium smegmatis</i> to Subinhibitory Rifampicin Exposure. <i>Frontiers in Medicine</i> , 2021, 8, 723667.	1.2	4
28	Synthesis and biological evaluation of bis-N ₂ ,N ₂ -(4-hydroxycoumarin-3-yl)ethylidene]-2,3-dihydroxysuccinodihydrazides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126911.	1.0	3
29	Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8854.	1.8	9
30	Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 582416.	1.8	6
31	Antimicrobial evaluation of neutral and cationic iridium(III) and rhodium(III) aminoquinoline-benzimidazole hybrid complexes. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112694.	2.6	21
32	Bioaerosol sampling of patients with suspected pulmonary tuberculosis: a study protocol. <i>BMC Infectious Diseases</i> , 2020, 20, 587.	1.3	10
33	Sensitivity optimisation of tuberculosis bioaerosol sampling. <i>PLoS ONE</i> , 2020, 15, e0238193.	1.1	10
34	Novel approach to estimate tuberculosis transmission in primary care clinics in sub-Saharan Africa: protocol of a prospective study. <i>BMJ Open</i> , 2020, 10, e036214.	0.8	4
35	Synthesis and in vitro antimycobacterial and antileishmanial activities of hydroquinone-triazole hybrids. <i>Medicinal Chemistry Research</i> , 2020, 29, 1387-1399.	1.1	12
36	6-Nitro-4-benzylquinolones exhibiting specific antitubercular activity. <i>Chemical Biology and Drug Design</i> , 2020, 96, 1387-1394.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Novel South African Rare Actinomycete <i>Kribbella speibonae</i> Strain SK5: A Prolific Producer of Hydroxamate Siderophores Including New Dehydroxylated Congeners. <i>Molecules</i> , 2020, 25, 2979.	1.7	11
38	Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues. <i>Bioorganic Chemistry</i> , 2020, 96, 103587.	2.0	14
39	Arrayed CRISPRi and quantitative imaging describe the morphotypic landscape of essential mycobacterial genes. <i>ELife</i> , 2020, 9, .	2.8	50
40	Sensitivity optimisation of tuberculosis bioaerosol sampling. , 2020, 15, e0238193.		0
41	Sensitivity optimisation of tuberculosis bioaerosol sampling. , 2020, 15, e0238193.		0
42	Sensitivity optimisation of tuberculosis bioaerosol sampling. , 2020, 15, e0238193.		0
43	Sensitivity optimisation of tuberculosis bioaerosol sampling. , 2020, 15, e0238193.		0
44	Sensitivity optimisation of tuberculosis bioaerosol sampling. , 2020, 15, e0238193.		0
45	Sensitivity optimisation of tuberculosis bioaerosol sampling. , 2020, 15, e0238193.		0
46	<i>Mycobacterium tuberculosis</i> Metabolism. <i>Microbiology Spectrum</i> , 2019, 7, .	1.2	19
47	Semisynthetic Antimycobacterial C-3 Silicate and C-3/C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma, and <i>Mycobacterium tuberculosis</i> culture. <i>ACS Infectious Diseases</i> , 2019, 5, 1634-1644.	1.8	22
48	Azaaurones as Potent Antimycobacterial Agents Active against MDR and XDR TB. <i>ChemMedChem</i> , 2019, 14, 1537-1546.	1.6	19
49	Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery. <i>Accounts of Chemical Research</i> , 2019, 52, 2340-2348.	7.6	15
50	Synthesis and antimycobacterial activity of disubstituted benzyltriazoles. <i>Medicinal Chemistry Research</i> , 2019, 28, 2279-2293.	1.1	20
51	<i>In Vitro</i> Efficacies, ADME, and Pharmacokinetic Properties of Phenoxazine Derivatives Active against <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	4
52	Expanding the anti-TB arsenal. <i>Science</i> , 2019, 363, 457-458.	6.0	4
53	Quinolone-isoniazid hybrids: synthesis and preliminary <i>in vitro</i> cytotoxicity and anti-tuberculosis evaluation. <i>MedChemComm</i> , 2019, 10, 326-331.	3.5	20
54	Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: Antimicrobial evaluation and mechanistic insights. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 121-133.	2.6	19

#	ARTICLE	IF	CITATIONS
55	Synthesis and biological evaluation of 2-chloro-3-[(thiazol-2-yl)amino]-1,4-naphthoquinones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1572-1575.	1.0	12
56	New Quinolone-Based Thiosemicarbazones Showing Activity Against <i>Plasmodium falciparum</i> and <i>Mycobacterium tuberculosis</i> . <i>Molecules</i> , 2019, 24, 1740.	1.7	15
57	Detection, survival and infectious potential of <i>Mycobacterium tuberculosis</i> in the environment: a review of the evidence and epidemiological implications. <i>European Respiratory Journal</i> , 2019, 53, 1802302.	3.1	26
58	Design, synthesis, and antimycobacterial activity of novel ciprofloxacin derivatives. <i>Chemical Biology and Drug Design</i> , 2019, 94, 1518-1536.	1.5	15
59	<i>Mycobacterium tuberculosis</i> Metabolism. , 2019, , 1107-1128.		0
60	Synthesis and biological screening of diethyl [N-(thiazol-2-yl)carbamoyl]methylphosphonates. <i>Arkivoc</i> , 2019, 2018, 110-118.	0.3	0
61	2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and <i>Mycobacterium tuberculosis</i> : Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. <i>ACS Infectious Diseases</i> , 2018, 4, 954-969.	1.8	49
62	Proteomic comparison of three clinical diarrhoeagenic drug-resistant <i>Escherichia coli</i> isolates grown on CHROMagar, STEC media. <i>Journal of Proteomics</i> , 2018, 180, 25-35.	1.2	16
63	Beyond the lab: Ethnobotany and knowing tuberculosis. <i>Medical Humanities</i> , 2018, 44, 285-292.	0.6	9
64	Editorial overview: Tuberculosis, malaria and schistosomiasis; understanding resistance and development of new drugs. <i>Current Opinion in Pharmacology</i> , 2018, 42, iv-vi.	1.7	2
65	Accessible and distinct decoquinone derivatives active against <i>Mycobacterium tuberculosis</i> and apicomplexan parasites. <i>Communications Chemistry</i> , 2018, 1, .	2.0	30
66	Death of <i>Mycobacterium tuberculosis</i> by <i>scpH</i> -arginine starvation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9658-9660.	3.3	12
67	A19, The impact of HIV-1 on the evolution of <i>Mycobacterium tuberculosis</i> . <i>Virus Evolution</i> , 2018, 4, .	2.2	0
68	Cinnamoyl-Oxaborole Amides: Synthesis and Their in Vitro Biological Activity. <i>Molecules</i> , 2018, 23, 2038.	1.7	17
69	Drug permeation and metabolism in <i>Mycobacterium tuberculosis</i> : Prioritising local exposure as essential criterion in new TB drug development. <i>IUBMB Life</i> , 2018, 70, 926-937.	1.5	27
70	DNA Replication in <i>Mycobacterium tuberculosis</i> . <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	29
71	The Influence of HIV on the Evolution of <i>Mycobacterium tuberculosis</i> . <i>Molecular Biology and Evolution</i> , 2017, 34, 1654-1668.	3.5	27
72	Antimicrobial activity of organometallic isonicotinyl and pyrazinyl ferrocenyl-derived complexes. <i>Dalton Transactions</i> , 2017, 46, 9875-9885.	1.6	48

#	ARTICLE	IF	CITATIONS
73	Susceptibility of <i>Mycobacterium tuberculosis</i> Cytochrome <i>c</i> Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome <i>c</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	49
74	Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10118-10134.	2.9	22
75	DNA Replication Fidelity in the <i>Mycobacterium tuberculosis</i> Complex. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1019, 247-262.	0.8	11
76	The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. <i>ACS Infectious Diseases</i> , 2017, 3, 5-17.	1.8	83
77	Genome-Wide Transposon Mutagenesis in <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium smegmatis</i> . <i>Methods in Molecular Biology</i> , 2017, 1498, 321-335.	0.4	17
78	Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. <i>Molecular Microbiology</i> , 2017, 103, 13-25.	1.2	22
79	Detection of <i>Mycobacterium tuberculosis</i> bacilli in bio-aerosols from untreated TB patients. <i>Gates Open Research</i> , 2017, 1, 11.	2.0	58
80	DNA Replication in <i>Mycobacterium tuberculosis</i> . , 2017, , 581-606.		1
81	Versatility of 7-Substituted Coumarin Molecules as Antimycobacterial Agents, Neuronal Enzyme Inhibitors and Neuroprotective Agents. <i>Molecules</i> , 2017, 22, 1644.	1.7	23
82	Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 75.	1.6	42
83	Synthesis and biological evaluation of (E)-cinnamic acid, (E)-2-styrylthiazole and (E)-2-[2-(naphthalen-1-yl)vinyl]thiazole derivatives. <i>Arkivoc</i> , 2017, 2016, 284-296.	0.3	4
84	Detection of <i>Mycobacterium tuberculosis</i> bacilli in bio-aerosols from untreated TB patients. <i>Gates Open Research</i> , 2017, 1, 11.	2.0	54
85	Effective Visualization of Tuberculosis Three-Drug Assays. , 2016, , .		0
86	Mono- and polynuclear ferrocenylthiosemicarbazones: Synthesis, characterisation and antimicrobial evaluation. <i>Journal of Organometallic Chemistry</i> , 2016, 819, 166-172.	0.8	11
87	Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6748-6757.	1.4	38
88	Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against <i>Mycobacterium tuberculosis</i> . <i>ACS Infectious Diseases</i> , 2016, 2, 714-725.	1.8	18
89	Defining a diagnostic gene signature for tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 170-171.	5.2	1
90	Synthesis, characterization and antimicrobial evaluation of mono- and polynuclear ferrocenyl-derived amino and imino complexes. <i>Journal of Organometallic Chemistry</i> , 2016, 809, 79-85.	0.8	11

#	ARTICLE	IF	CITATIONS
91	Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC). PLoS ONE, 2016, 11, e0146658.	1.1	40
92	The Complex Mechanism of Antimycobacterial Action of 5-Fluorouracil. Chemistry and Biology, 2015, 22, 63-75.	6.2	90
93	Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization. Bioorganic and Medicinal Chemistry, 2015, 23, 7240-7250.	1.4	41
94	Pyrrolo[3,4- <i>c</i>]pyridine-1,3(2 <i>H</i>)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. Journal of Medicinal Chemistry, 2015, 58, 9371-9381.	2.9	74
95	Mycobacterium tuberculosis Metabolism. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021121-a021121.	2.9	91
96	Diversity and disease pathogenesis in Mycobacterium tuberculosis. Trends in Microbiology, 2015, 23, 14-21.	3.5	64
97	Targeted Gene Knockout and Essentiality Testing by Homologous Recombination. Methods in Molecular Biology, 2015, 1285, 131-149.	0.4	17
98	Translating genomics research into control of tuberculosis: lessons learned and future prospects. Genome Biology, 2014, 15, 514.	3.8	2
99	Shortening Treatment for Tuberculosis " Back to Basics. New England Journal of Medicine, 2014, 371, 1642-1643.	13.9	57
100	The impact of drug resistance on <i>Mycobacterium tuberculosis</i> physiology: what can we learn from rifampicin?. Emerging Microbes and Infections, 2014, 3, 1-11.	3.0	100
101	Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 560-564.	1.0	56
102	Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites. MedChemComm, 2014, 5, 502-506.	3.5	16
103	Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2014, 69, 292-302.	1.3	123
104	Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery. Bioorganic and Medicinal Chemistry, 2014, 22, 4453-4461.	1.4	16
105	Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2985-2990.	1.0	31
106	Nucleotide Metabolism and DNA Replication. Microbiology Spectrum, 2014, 2, .	1.2	31
107	Complex genetics of drug resistance in Mycobacterium tuberculosis. Nature Genetics, 2013, 45, 1107-1108.	9.4	26
108	Synthesis, Characterization, and Pharmacological Evaluation of Silicon-Containing Aminoquinoline Organometallic Complexes As Antiplasmodial, Antitumor, and Antimycobacterial Agents. Organometallics, 2013, 32, 141-150.	1.1	48

#	ARTICLE	IF	CITATIONS
109	Synthesis and Antiplasmodial and Antimycobacterial Evaluation of New Nitroimidazole and Nitroimidazooxazine Derivatives. ACS Medicinal Chemistry Letters, 2013, 4, 128-131.	1.3	47
110	Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2013, 70, 589-593.	2.6	26
111	Vitamin B ₁₂ metabolism in <i>Mycobacterium tuberculosis</i> . Future Microbiology, 2013, 8, 1405-1418.	1.0	58
112	DNA Metabolism in Mycobacterial Pathogenesis. Current Topics in Microbiology and Immunology, 2013, 374, 27-51.	0.7	18
113	A vitamin B ₁₂ transporter in <i>Mycobacterium tuberculosis</i> . Open Biology, 2013, 3, 120175.	1.5	83
114	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	0.8	33
115	A Pseudokinase Debut at the Mycobacterial Cell Wall. Science Signaling, 2012, 5, pe3.	1.6	5
116	Approaches to target identification and validation for tuberculosis drug discovery: a UCT perspective. South African Medical Journal, 2012, 102, 457.	0.2	3
117	Tuberculosis Drug Discovery: Target Identification and Validation. , 2012, , 53-84.		0
118	A novel inducible mutagenesis system in Mycobacterium tuberculosis. FASEB Journal, 2012, 26, 222.1.	0.2	2
119	Making ends meet in mycobacteria. Molecular Microbiology, 2011, 79, 283-287.	1.2	7
120	Role of the DinB Homologs Rv1537 and Rv3056 in <i>Mycobacterium tuberculosis</i> . Journal of Bacteriology, 2010, 192, 2220-2227.	1.0	61
121	Essential roles for <i>imuA</i> - and <i>imuB</i> -encoded accessory factors in DnaE2-dependent mutagenesis in <i>Mycobacterium tuberculosis</i> . Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13093-13098.	3.3	113
122	The role of DNA repair in M. tuberculosis pathogenesis. Drug Discovery Today Disease Mechanisms, 2010, 7, e5-e11.	0.8	13
123	Function and Regulation of Class I Ribonucleotide Reductase-Encoding Genes in Mycobacteria. Journal of Bacteriology, 2009, 191, 985-995.	1.0	48
124	IS1096-mediated DNA rearrangements play a key role in genome evolution of Mycobacterium smegmatis. Tuberculosis, 2008, 88, 399-409.	0.8	16
125	Functional Characterization of a Vitamin B ₁₂ -Dependent Methylmalonyl Pathway in <i>Mycobacterium tuberculosis</i> : Implications for Propionate Metabolism during Growth on Fatty Acids. Journal of Bacteriology, 2008, 190, 3886-3895.	1.0	214
126	A Riboswitch Regulates Expression of the Coenzyme B ₁₂ -Independent Methionine Synthase in Mycobacterium tuberculosis : Implications for Differential Methionine Synthase Function in Strains H37Rv and CDC1551. Journal of Bacteriology, 2007, 189, 3655-3659.	1.0	76

#	ARTICLE	IF	CITATIONS
127	The survival kit of Mycobacterium tuberculosis. Nature Medicine, 2007, 13, 282-284.	15.2	62
128	A derivative of Mycobacterium smegmatis mc2155 that lacks the duplicated chromosomal region. Tuberculosis, 2006, 86, 438-444.	0.8	14
129	Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy. Clinical Microbiology Reviews, 2006, 19, 558-570.	5.7	129
130	Mycobacterial genetics in target validation. Drug Discovery Today: Technologies, 2004, 1, 93-98.	4.0	8
131	Ribonucleotide Reduction in Mycobacterium tuberculosis : Function and Expression of Genes Encoding Class Ib and Class II Ribonucleotide Reductases. Infection and Immunity, 2003, 71, 6124-6131.	1.0	65
132	Arylquinolinecarboxamides: Synthesis, in vitro and in silico studies against Mycobacterium tuberculosis. Journal of Heterocyclic Chemistry, 0, , .	1.4	1
133	Nucleotide Metabolism and DNA Replication. , 0, , 633-656.		1
134	Investigation of quinoloneâ€ethered aminoguanidine as novel antibacterial agents. Archiv Der Pharmazie, 0, , .	2.1	3